Agreement - July 15, 2024
SmartCella raises EUR 50 million and enters license agreement
SmartCella has announced a new share issue to accelerate growth and support commercialization of the Extroducer and the company’s cell and mRNA operations. The share issue was supported by existing large institutional investors such as Fjärde AP-fonden, AMF Pension and SEB-Stiftelsen, as well as a new long-term strategic investor, AstraZeneca (committing to approximately half of […]
Financing - July 11, 2024
Orion and MSD announce mutual exercise of option
Orion Corporation and MSD have announced that notice has been provided of the mutual exercise of an option to convert the companies’ ongoing co-development and co-commercialization agreement for opevesostat, an investigational CYP11A1 inhibitor, and other candidates targeting CYP11A1 into an exclusive global license for MSD. “The conversion of this collaboration into a license agreement allows […]
Business article - July 9, 2024
Hadean Ventures co-leads investment into SciRhom
Hadean Ventures co-led the EUR 63 million Series A financing round, together with a consortium of international investors. In conjunction with this investment, Georgina Askeland, Senior Associate at Hadean Ventures, will join SciRhom’s board of directors. “SciRhom has a unique approach that ticks all the boxes in I&I. In one stroke, their highly selective iRhom2 […]
Business article - July 9, 2024
Kvantify secures EUR 10 million seed round
The round is led by Danish VC Dreamcraft, together with biotech investor Lundbeckfonden BioCapital and the private investment company 2degrees. The investment will accelerate the development of Kvantify’s solutions that aim to leverage quantum computing to address complex problems in drug discovery and beyond. It will also boost the further development of quantum algorithms for […]
Biotech Business - July 8, 2024
Herantis receives funding from The Michael J. Fox Foundation and the Parkinson’s Virtual Biotech
The research funding of EUR 3.6 million will finance Herantis’ Phase 1b clinical trial and expand the on-going biomarker project, it states. “We are proud to be awarded funding for the HER-096 Phase 1b clinical trial from Parkinson’s Virtual Biotech and The Michael J. Fox Foundation, two prestigious organizations in this field. This external validation […]
Financing - June 26, 2024
Novo Nordisk to invest USD 4.1 billion to build a manufacturing facility in USA
Novo Nordisk has announced plans to invest approx DKK 27 billion to build a second fill and finishing manufacturing facility in Clayton, North Carolina, and grow its ability to produce current and future injectable treatments for people with obesity and other serious chronic diseases. Marking one of the largest manufacturing investments in Novo Nordisk’s history, […]
